<DOC>
	<DOCNO>NCT01384734</DOCNO>
	<brief_summary>The purpose study assess safety , efficacy , tolerability pharmacokinetics four dos BMS-663068 Raltegravir ( RAL ) + Tenofovir Disoproxil Fumarate ( TDF ) . At least 1 dose BMS-663068 identify safe , well tolerate , efficacious combine RAL + TDF treatment-experienced HIV-1 infected subject .</brief_summary>
	<brief_title>HIV Attachment Inhibitor Treat Human Immunodeficiency Virus 1 ( HIV-1 ) Infections</brief_title>
	<detailed_description>Masking : Double-blind BMS-6630368 treatment group Week 24 Primary Endpoint analysis , open label . The reference group open-label . Arms : 5 ( 4 BMS-663068 treatment group 1 reference group ) Intervention Model : Parallel ( unblinding Week 24 primary endpoint analysis )</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Plasma HIV1 RNA ≥ 1000 copies/ml Screening Treatment experience antiretroviral therapy ( exclude integrase inhibitor ) Screening PhenoSense® Entry indicate BMS626529 inhibitory concentration ( IC ) 50 &lt; 0.1 μM Cluster differentiation ( CD ) 4+ Tcell count &gt; 50 cells/mm3 History ( evidence Screening ) genotypic resistance component study regimen [ Tenofovir Disoproxil Fumarate ( TDF ) , Atazanavir ( ATV ) , Raltegravir ( RAL ) ] Certain laboratory electrocardiogram ( ECG ) value</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>